Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
NCT06345404
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Corvus Clinical Trials Information, South San Francisco, California
Conditions: Atopic Dermatitis
Register for Updates
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
NCT06424106
Recruiting
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
04/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: PreDiabetes
Register for Updates
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC
NCT06511596
Recruiting
This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amnion Chorion (BR-AC) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for debridement, wound dressings, and off-loading. Weekly subject visits will help monitor compliance in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Site 02, San Francisco, California +10 locations
Conditions: Diabetic Foot Ulcer
Register for Updates
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406
Recruiting
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: HonorHealth Research Insisute, Scottsdale, Arizona +14 locations
Conditions: Metastatic Uveal Melanoma
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Palo Verde Hematology Oncology, Glendale, Arizona +144 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
NCT06712446
Recruiting
The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/14/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Methamphetamine Use Disorder
Register for Updates
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
Recruiting
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Ava... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/14/2025
Locations: Retinal Consultants of AZ, Phoenix, Arizona +9 locations
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
Psychobiological Responses Following Exercise and Brain Stimulation
NCT06874595
Recruiting
Anxiety disorders are the most common mental health diagnosis in the US; 19.1% of U.S. adults (23.4% for females and 14.3% for males). In addition, the Global Burden of Disease study (2010) found that anxiety disorders were the sixth leading cause of disability (years of life lived with disability). These debilitating disorders are characterized by excessive worry and fear about everyday situations, and physical symptoms including restlessness, being easily fatigued, difficulty concentrating, ir... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/14/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Psychological
Register for Updates
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT06929286
Recruiting
The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/14/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Non-Muscle Invasive Bladder Cancer
Register for Updates
Maintenance rTMS for Depression (Maitr-De)
NCT06938841
Recruiting
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS in individuals with TRD who have previously responded to an acute course of rTMS. In the R61 phase of the study, we will recruit 75 participants across three study sites, the University of California... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: University of California, San Diego, San Diego, California +2 locations
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
NCT03053141
Recruiting
The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Cardiac Arrythmias
Register for Updates
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
NCT03899987
Recruiting
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. EC Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates